{"nctId":"NCT01392547","briefTitle":"Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors","startDateStruct":{"date":"2011-07"},"conditions":["Congenital Bleeding Disorder","Haemophilia A With Inhibitors","Haemophilia B With Inhibitors"],"count":72,"armGroups":[{"label":"rFVIIa","type":"EXPERIMENTAL","interventionNames":["Drug: eptacog alfa (activated)"]},{"label":"vatreptocog alfa","type":"EXPERIMENTAL","interventionNames":["Drug: vatreptacog alfa (activated)"]}],"interventions":[{"name":"vatreptacog alfa (activated)","otherNames":[]},{"name":"eptacog alfa (activated)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male patient with clinical diagnosis of congenital haemophilia A or B and inhibitors to coagulation factors VIII or IX\n* Minimum of five bleeds requiring haemostatic drug treatment within the previous 12 months at trial entry\n\nExclusion Criteria:\n\n* Previous participation in this trial defined as withdrawal after administration of trial product\n* Patient has received an investigational medicinal product within 30 days prior to this trial\n* Congenital or acquired coagulation disorders other than haemophilia A or B\n* Any clinical signs or known history of arterial thrombotic events or of deep venous thrombosis or pulmonary embolism (as defined by available medical records)\n* Platelet count of less than 50,000 platelets/mcL (at the screening visit)\n* ALAT (alanine-transaminase) of more than 3 times the upper normal limit (according to laboratory reference ranges)\n* Factor VIII/IX Immune Tolerance Induction regimen planned to occur during the trial\n* Ongoing bleeding prophylaxis regimens or planned bleeding prophylaxis to occur during the trial\n* HIV (Human Immunodeficiency Virus) positive with current CD4+ count of less than 200/mcL (defined by medical records)","healthyVolunteers":false,"sex":"MALE","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Effective Bleeding Control Defined as no Additional Haemostatic Medication (Other Than Trial Product) Given","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"318","spread":null},{"groupId":"OG001","value":"211","spread":null}]}]}]},{"type":"SECONDARY","title":"Effective and Sustained Bleeding Control","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"268","spread":null},{"groupId":"OG001","value":"163","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Doses of Trial Product Given for Each Acute Bleed","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"195","spread":null},{"groupId":"OG001","value":"142","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Adverse Events","description":"Any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunogenicity (Inhibitor Development)","description":"Immunogenicity was tested by formation of neutralising antibodies towards vatreptacog alfa and/or FVII. Radioimmunoassay using \\[125I\\]-labelled vatreptacog alfa or rFVIIa was used to screen plasma samples for development of anti-drug antibodies","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":72},"commonTop":["Drug specific antibody present"]}}}